Showing 1 - 20 of 34 Items
Showing 1 - 20 of 34 Items
Sort By: Relevance
Journal Article
|Research
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health
BACKGROUND
There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...
Journal Article
|Research
2005-07-01 • AIDS Care
2005-07-01 • AIDS Care
The health authorities have recently accepted the routine provision of highly active antiretroviral therapy to persons living with AIDS in South Africa. There is a need to investigate th...
Journal Article
|Short Report
2018-03-13 • Lancet Infectious Diseases
2018-03-13 • Lancet Infectious Diseases
Treatment for drug-resistant tuberculosis is largely delivered through standardised, empirical combination regimens in low-resource, high-burden settings. However, individualised treatme...
Journal Article
|Letter
2015-12-01 • European Respiratory Journal
2015-12-01 • European Respiratory Journal
Journal Article
|Research
2014-04-01 • International Journal of Tuberculosis and Lung Disease
2014-04-01 • International Journal of Tuberculosis and Lung Disease
SETTING: Khayelitsha, South Africa, a peri-urban township with high burdens of tuberculosis (TB), drug-resistant tuberculosis (DR-TB), and human immunodeficiency virus (HIV) infection.
Journal Article
|Research
2015-11-10 • PLOS One
2015-11-10 • PLOS One
SETTING
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co-infection.
OBJECTIVE
To describe time to antiretroviral trea...
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co-infection.
OBJECTIVE
To describe time to antiretroviral trea...
Journal Article
|Research
2022-05-02 • Lancet Infectious Diseases
2022-05-02 • Lancet Infectious Diseases
BACKGROUND
There is a need for short and safe all-oral treatment of rifampicin-resistant tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients wi...
There is a need for short and safe all-oral treatment of rifampicin-resistant tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients wi...
Journal Article
|Letter
2013-01-01 • Lancet Infectious Diseases
2013-01-01 • Lancet Infectious Diseases
Journal Article
|Short Report
2019-09-14 • Lancet
2019-09-14 • Lancet
Children bear a substantial burden of suffering when it comes to tuberculosis. Ironically, they are often left out of the scientific and public health advances that have led to important...
Journal Article
|Research
2021-11-12 • Lancet Infectious Diseases
2021-11-12 • Lancet Infectious Diseases
BACKGROUND
Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did...
Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did...
Journal Article
|Commentary
2020-11-01 • International Journal of Tuberculosis and Lung Disease
2020-11-01 • International Journal of Tuberculosis and Lung Disease
Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB) and multidrug-resistant TB ...
Journal Article
|Research
2018-09-08 • Lancet
2018-09-08 • Lancet
BACKGROUND
Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...
Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...
Journal Article
|Research
2018-02-13 • Lancet Infectious Diseases
2018-02-13 • Lancet Infectious Diseases
BACKGROUND
Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients ...
Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients ...
Journal Article
|Research
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for t...
Journal Article
|Letter
2020-04-02 • International Journal of Tuberculosis and Lung Disease
2020-04-02 • International Journal of Tuberculosis and Lung Disease
Journal Article
|Research
2018-10-25 • European Respiratory Journal
2018-10-25 • European Respiratory Journal
Background: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a ...
Journal Article
|Research
2017-05-18 • PLOS One
2017-05-18 • PLOS One
BACKGROUND
Daily directly-observed therapy (DOT) is recommended for rifampicin-resistant tuberculosis (RR-TB) patients throughout treatment. We assessed the impact of self-administer...
Daily directly-observed therapy (DOT) is recommended for rifampicin-resistant tuberculosis (RR-TB) patients throughout treatment. We assessed the impact of self-administer...
Journal Article
|Letter
2015-04-02 • European Respiratory Journal
2015-04-02 • European Respiratory Journal
Journal Article
|Commentary
2012-03-01 • Lancet Infectious Diseases
2012-03-01 • Lancet Infectious Diseases
Journal Article
|Research
2015-07-19 • International Journal of Tuberculosis and Lung Disease
2015-07-19 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
South Africa has a large burden of extensively drug-resistant tuberculosis (XDR-TB); only 15% of XDR-TB patients have successful outcomes.
OBJECTIVE
To descri...
South Africa has a large burden of extensively drug-resistant tuberculosis (XDR-TB); only 15% of XDR-TB patients have successful outcomes.
OBJECTIVE
To descri...